Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

1 results found

Title
Status

 

CLIC-02 - CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Open

CLIC-02 - CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Go to Health Care Provider version

DiagnosisB-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell LymphomaStudy StatusOpen
PhaseI
Age1 Year and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: CLIC-2201
Last Posted Update2025-07-02
ClinicalTrials.gov #NCT06208735
International Sponsor
British Columbia Cancer Agency
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Joerg Kruger
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

 

 This study is eligible for STEP-1 funding. Find more information here

 

 

This is an early-phase clinical trial testing a new kind of treatment called CLIC-2201. It uses a patient’s own immune cells, which are specially modified to better recognize and fight certain types of cancer that affect B cells. This treatment is being offered to patients whose cancer has come back or has not responded to other treatments.

Inclusion Criteria

Cohort A (B cell lymphoma):

  • Must be 18 years of age or older of age at time of consent
  • You have B cell lymphoma that has come back or hasn’t gotten better with other treatments
  • You’ve already tried at least two treatments, or had a stem cell transplant, or CAR-T therapy before
  • You meet the necessary organ function and bloodwork requirements 
  • You must be up and about at least half of your waking hours 
  • If you could become pregnant or get someone pregnant, you agree to use birth control for a year after the treatment

 

Cohort B (B-ALL):

  • Must be between 1 and 21 years old, and you (and/or your parent or guardian) agree to join the study
  • You have B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn’t gotten better with other treatments.
  • You’ve already tried at least two treatments, or had a stem cell transplant, or CAR-T therapy before
  • If you had a treatment that targeted CD22, your cancer must still show signs of that marker
  • You meet the necessary organ function and bloodwork requirements 
  • You must be up and about at least half of your waking hours 
  • If you could become pregnant or get someone pregnant, you agree to use birth control for a year after the treatment
  • You are okay with a bone marrow biopsy before starting the study

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

 

Publications

Both Cohorts A and B

  • Any uncontrolled or serious active infection at the time of enrolment.
  • Active autoimmune disease requiring immunosuppressive therapy within 4 weeks of enrolment.
  • Live vaccine ≤6 weeks prior to enrolment
  • Active Graft Versus Host Disease (GVHD) requiring systemic immunosuppressive therapy within 4 weeks of enrolment.
  • Treatment with any of the following in the specified time period before leukapheresis:
    • Allogeneic HCT within 3 months,
    • Autologous HCT within 3 months,
    • CD19 CAR-T cell infusion within 3 months,
    • Donor lymphocyte infusion (DLI) within 3 months,
    • Bendamustine within the last 6 months,
    • Any investigational agent within 30 days or 5 half-lives (whichever is shorter),
    • Systemic administration of therapeutic dose corticosteroids (>20 mg/day prednisone or equivalent for adults and ≥ 12 mg/m2/day for paediatric participants) within 7 days prior to leukapheresis.
    • Immunosuppressive therapies (i.e., calcineurin inhibitors, methotrexate, mycophenolate, rapamycin) within 4 weeks.
    • Oral chemotherapy agents (i.e., venetoclax) within 5 half-lives. An exception to this is that bruton tyrosine kinase (BTK) inhibitors like ibrutinib can be continued in participants with mantle cell lymphoma throughout the trial period.
  • Other concurrent malignancy or a prior malignancy treated within the past 2 years, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease.
  • Concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure or immunodeficiency syndrome.
  • Active (confirmed by PCR) hepatitis B or hepatitis C at time of screening confirmed by PCR.
  • Any Human Immunodeficiency Virus (HIV) infection at time of screening.
  • Hypersensitivity to fludarabine or cyclophosphamide.
  • Any allergy to gentamycin or its derivatives
  • Pregnant or nursing participants.